Catalog No.S3041 Synonyms: L-DOPS

For research use only.

Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

Droxidopa Chemical Structure

CAS No. 23651-95-8

Purity & Quality Control

Choose Selective Adrenergic Receptor Inhibitors

Other Adrenergic Receptor Products

Biological Activity

Description Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
Features An artificial amino acid.
Adrenergic Receptor [1]
In vitro

Droxidopa is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. [1] Droxidopa is well tolerated. [2] Droxidopa could exert its pressor effect in three different ways: a) as a central stimulator of sympathetic activity; b) as a peripheral sympathetic neurotransmitter; c) as a circulating hormone. Droxidopa taken alone increases standing blood pressure. [3] Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine and epinephrine from within the brain. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2 cells MlvRSpVv[3Srb36gZZN{[Xl? NWP1PYZoOjRiaB?= M1rIcWFkfGm4YYTpc44hd2ZiaIXtZY4hWFiUIHX4dJJme3OnZDDpckBpfW2jbjDI[ZBIOiBqRGDYMVIqKGOnbHzzJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDDXXA{STRiYX\0[ZIhOjRiaILzJIJ6KGy3bXnu[ZNk\W62IHHuZYx6e2m|LDDFR|UxRTBwMEC0JO69VQ>? NULKV|J[OjB7Nk[wOFM>
In vivo The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow. Droxidopa-treated rats also showed a decreased ratio of p-eNOS/eNOS and p-AKT/AKT and increased activity of RhoK in SMA[5].

Protocol (from reference)

Animal Research:


  • Animal Models: biliary duct-ligated (BDL) rats
  • Dosages: 25-50 mg/kg
  • Administration: oral administration

Solubility (25°C)

In vitro

DMSO Insoluble
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 213.19


CAS No. 23651-95-8
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03446807 Not yet recruiting Drug: Droxidopa|Drug: Placebo Oral Tablet Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy Loma Linda University|H. Lundbeck A/S December 2021 Phase 2
NCT04977388 Recruiting Drug: Droxidopa|Other: Placebo Menkes Disease|Occipital Horn Syndrome Stephen G. Kaler MD|Nationwide Children''s Hospital July 12 2021 Phase 1|Phase 2
NCT03173781 Completed Drug: droxidopa|Drug: Placebo Parkinson''s Disease Colorado Springs Neurological Associates|H. Lundbeck A/S April 2016 Not Applicable
NCT01331122 Withdrawn Drug: droxidopa Gait Disorders Neurologic Chelsea Therapeutics April 2012 Phase 1|Phase 2
NCT01370512 Completed Drug: Droxidopa|Drug: Pyridostigmine Bromide Orthostatic Hypotension Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS) November 2011 Phase 2
NCT01354158 Completed Drug: Droxidopa Spinal Cord Injury|Hypotension Bronx VA Medical Center|Chelsea Therapeutics May 2011 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Droxidopa | Droxidopa ic50 | Droxidopa price | Droxidopa cost | Droxidopa solubility dmso | Droxidopa purchase | Droxidopa manufacturer | Droxidopa research buy | Droxidopa order | Droxidopa mouse | Droxidopa chemical structure | Droxidopa mw | Droxidopa molecular weight | Droxidopa datasheet | Droxidopa supplier | Droxidopa in vitro | Droxidopa cell line | Droxidopa concentration | Droxidopa nmr